These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23826582)

  • 1. The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Blood Res; 2013 Jun; 48(2):128-32. PubMed ID: 23826582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
    Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
    Takahashi K; Patel KP; Kantarjian H; Luthra R; Pierce S; Cortes J; Verstovsek S
    Blood; 2013 Nov; 122(23):3784-6. PubMed ID: 24068492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
    Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm].
    Liu Y; Liu C; He N; Wang M; Zhang X; Tang D; Ji C; Ma D
    Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):191-5. PubMed ID: 25854460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
    He ZP; Tian HY; Tan M; Wu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
    Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
    Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
    Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
    Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms.
    Demiriz IŞ; Kazanci MH; Menfaatli E; Jafari-Gharabaghlou D; Zarghami N
    Mol Biol Rep; 2023 Jul; 50(7):5687-5695. PubMed ID: 37209326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of different methodologies to detect the
    Didone A; Nardinelli L; Marchiani M; Ruiz ARL; de Lima Costa AL; Lima IS; Santos NM; Sanabani SS; Bendit I
    Pract Lab Med; 2016 Apr; 4():30-37. PubMed ID: 28856190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2
    Fan W; Cao W; Shi J; Gao F; Wang M; Xu L; Wang F; Li Y; Guo R; Bian Z; Li W; Jiang Z; Ma W
    Ann Hematol; 2023 Jul; 102(7):1745-1759. PubMed ID: 37233774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
    Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
    Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.